目的 探讨神经内镜内技术（INET）在治疗亚急性-慢性和慢性分隔硬膜下血肿中的安全性、有效性和临床应用价值。方法 采用非随机同期对照的研究方法将2015-05～2018-04符合纳入标准的74例患者分成INET治疗组（INET组）35例和钻孔引流治...目的 探讨神经内镜内技术（INET）在治疗亚急性-慢性和慢性分隔硬膜下血肿中的安全性、有效性和临床应用价值。方法 采用非随机同期对照的研究方法将2015-05～2018-04符合纳入标准的74例患者分成INET治疗组（INET组）35例和钻孔引流治疗组（对照组）39例。记录并比较两组间的手术时间、硬膜下引流管（SDT）放置时间、颅内感染率及术后随访1个月时的Bender分级和6个月的血肿复发率。建立多参数Logistic回归模型，分析6个月内与复发相关的危险因素。结果 INET组手术时间长于对照组［（64.4±13.6）min vs. （44.1±10.8）min，P=0.00］，但其术后随访6个月内的血肿复发率（2.9% vs. 23.0%，P=0.04）和SDT放置时间均低于对照组［（2.1±0.7）d vs. （3.9±0.8）d,P=0.00］；颅内感染率在两组间比较差异无统计学意义（0.0 vs. 5.1%，P=0.52）。随访1个月时的Bender分级总体有效率（100% vs. 89.7%，P=0.15）两组间比较差异无统计学意义，但恢复至Bender 0级无症状患者的比率INET组高于对照组（94.2% vs. 76.9%，P=0.04）。多参数Logistic回归分析显示，应用INET手术（OR 3.62, 95%CI1.202～10.911, P=0.02）、年龄在65岁及以下（OR1.65, 95%CI1.051～2.602, P=0.03）和单侧硬膜下血肿（OR1.61, 95%CI 1.067～2.418, P=0.02）是术后复发率降低的独立影响因素。结论 INET能够降低亚急性-慢性和慢性分隔硬膜下血肿的术后复发率，改善临床预后，是治疗该类疾病的一种安全、有效的新手术方法。展开更多
The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Al...The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique（INET） consists of two of our patented inventions： a transparent sheath（Patent No. ZL 200820046232.0） and a hematoma aspirator（Patent No. ZL 201520248717.8）. This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35（19 men and 16 women, aged 53.2 ± 8.7 years） in the INET group and 30（17 men and 13 women, aged 51.5 ± 7.9 years） in the control group（extraventricular drainage plus urokinase thrombolytic therapy）. Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with Clinical Trials.gov（NCT02515903）.展开更多
目的分析透明内镜导鞘联合神经内镜在中等量(30~60 m L)高血压脑出血微创手术中的应用效果。方法回顾性分析广州中医药大学顺德医院脑病科自2016年8月至2018年1月应用透明内镜导鞘联合神经内镜手术清除16例中等量高血压脑出血的临床资...目的分析透明内镜导鞘联合神经内镜在中等量(30~60 m L)高血压脑出血微创手术中的应用效果。方法回顾性分析广州中医药大学顺德医院脑病科自2016年8月至2018年1月应用透明内镜导鞘联合神经内镜手术清除16例中等量高血压脑出血的临床资料及疗效。结果 16例平均手术切口长度4.5 cm;手术时间(2.3±0.8)h;术中出血量为(90.5±12.4)m L;术后第1天血肿清除率为70%~80%1例,80%~90%者3例,90%以上者12例。术后肺部感染2例,无再出血及颅内感染病例。术后3个月GOS评分恢复良好7例,轻度残疾8例,重度残疾1例。结论透明内镜导鞘联合神经内镜治疗中等量高血压脑出血具有微创、手术时间短、出血少、可直视下止血、血肿清除率高、术后再出血率低、并发症少、预后好等优点,值得临床推广应用。展开更多
文摘目的 探讨神经内镜内技术（INET）在治疗亚急性-慢性和慢性分隔硬膜下血肿中的安全性、有效性和临床应用价值。方法 采用非随机同期对照的研究方法将2015-05～2018-04符合纳入标准的74例患者分成INET治疗组（INET组）35例和钻孔引流治疗组（对照组）39例。记录并比较两组间的手术时间、硬膜下引流管（SDT）放置时间、颅内感染率及术后随访1个月时的Bender分级和6个月的血肿复发率。建立多参数Logistic回归模型，分析6个月内与复发相关的危险因素。结果 INET组手术时间长于对照组［（64.4±13.6）min vs. （44.1±10.8）min，P=0.00］，但其术后随访6个月内的血肿复发率（2.9% vs. 23.0%，P=0.04）和SDT放置时间均低于对照组［（2.1±0.7）d vs. （3.9±0.8）d,P=0.00］；颅内感染率在两组间比较差异无统计学意义（0.0 vs. 5.1%，P=0.52）。随访1个月时的Bender分级总体有效率（100% vs. 89.7%，P=0.15）两组间比较差异无统计学意义，但恢复至Bender 0级无症状患者的比率INET组高于对照组（94.2% vs. 76.9%，P=0.04）。多参数Logistic回归分析显示，应用INET手术（OR 3.62, 95%CI1.202～10.911, P=0.02）、年龄在65岁及以下（OR1.65, 95%CI1.051～2.602, P=0.03）和单侧硬膜下血肿（OR1.61, 95%CI 1.067～2.418, P=0.02）是术后复发率降低的独立影响因素。结论 INET能够降低亚急性-慢性和慢性分隔硬膜下血肿的术后复发率，改善临床预后，是治疗该类疾病的一种安全、有效的新手术方法。
基金funded by a grant from the Clinical Research Project of Shenzhen Health and Family Planning Commission in China,No.SZLY2018007a grant from the Science and Technology Planning Project of Shenzhen City of China,No.JCYJ 20150403101028210+2 种基金a grant from the Science and Technology Development and Cultivation Project of Southern Medical University of China,No.KJ 20161115the Guangdong Provincial Medical Research Fund in China,No.A2016545the Shenzhen Health Planning Commission Research Fund in China,No.201601013,201506009
文摘The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique（INET） consists of two of our patented inventions： a transparent sheath（Patent No. ZL 200820046232.0） and a hematoma aspirator（Patent No. ZL 201520248717.8）. This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35（19 men and 16 women, aged 53.2 ± 8.7 years） in the INET group and 30（17 men and 13 women, aged 51.5 ± 7.9 years） in the control group（extraventricular drainage plus urokinase thrombolytic therapy）. Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with Clinical Trials.gov（NCT02515903）.
